AZD-3514 is an anticancer chemotherapeutic that downregulates androgen receptor levels and inhibits nuclear translocation of androgen receptors. This compound exhibits efficacy in prostate cancer subjects in clinical settings. In vivo, AZD-3514 suppresses tumor growth. AZD-3514 also inhibits seminal vesicle development in juvenile animal models.
| Cas No. | 1240299-33-5 |
|---|---|
| Purity | ≥98% |
| Formula | C25H32F3N7O2 |
| Formula Wt. | 519.57 |
| IUPAC Name | 1-{4-[2-(4-{1-[3-(Trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazin-6-yl]-4-piperidinyl}phenoxy)ethyl]-1-piperazinyl}ethanone |
| Synonym | AZD3514 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | A9713 Info Sheet PDF |
|---|
Omlin A, Jones RJ, van der Noll R, et al. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. Invest New Drugs. 2015 Jun;33(3):679-90. PMID: 25920479.
Loddick SA, Ross SJ, Thomason AG, et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27. PMID: 23861347.
Bradbury RH, Acton DG, Broadbent NL, et al. Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1945-8. PMID: 23466225.
